A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a new study from researchers.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
A certification program in blood and marrow transplantation nursing is being offered by the Oncology Nursing Certification Corporation, with the first BMTCN examination scheduled for February 2014.
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
A new mathematical model suggests that proper risk assessment for the risk of infection with cancer chemotherapy needs to evaluate both the quantity and quality of white blood cells. The model was built by Weizmann Institute mathematicians in collaboration with physicians from the Meir Medical Center in Kfar Saba and from the Hoffman-La Roche research center in Basel, Switzerland.
An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.
Persons aged 16-39 with acute lymphoblastic leukemia fared better with pediatric-inspired chemotherapy regimens than with typical adult treatment.
When induction therapy fails in acute lymphoblastic leukemia, some youths have better outcomes with more chemotherapy than with stem cell transplant.
Few women of childbearing age who are diagnosed with cancer are taking steps to preserve their fertility during treatment.
The ancient Eastern medicinal art can relieve one of the most distressing effects of cancer and cancer treatment: fatigue.
A new initiative launched by CDC is designed to reduce the risk of life-threatening infection in cancer patients undergoing chemotherapy.
A regimen using minimal-intensity radiation therapy before bone marrow or stem cell transplantation may work for older patients who cannot tolerate stronger pretransplant treatment.
A genetic defect found on the GATA2 gene predisposes people to acute myeloid leukemia (AML) and myelodysplasia, researchers have learned.
A small study has demonstrated an improved process for making half-matched bone marrow or stem cell transplants for persons with blood cancer more successful.
Glioblastoma treatment may be made more effective by introducing a chemotherapy-resistant gene into normal bone marrow stem cells to protect them from the toxic effects of chemotherapy.
The program, outlined by Lisa Privitere, RN, BSN, OCN®, BMT, RPCI, and colleagues, in a presentation at the Oncology Nursing Society 36th Annual Congress, follows the story of a young girl (the orientee) on an adventure attempting to make sense of her new world, growing up and forever being changed to the White Rabbit (the preceptor) carrying a watch, always in a hurry.
The safety and efficiency of bone marrow transplants may improve due to the discovery of a rare molecule that establishes blood stem cells in their niche within the bone marrow.
A study published in Cancer found that African-Americans and women are less likely to undergo bone marrow transplantation to treat their cancer.
The OnControl Bone Marrow System has been made available by Vidacare for use by clinicians to perform bone marrow aspiration and biopsy procedures.
Scientists have improved a method for bone marrow transplantation from mismatched donors that would help restore the immune system quicker, according to findings presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|